Health · DR Congo
Why Ebola's Bundibugyo Strain Still Has No Licensed Vaccine as DR Congo Outbreak Continues
Researchers say the Bundibugyo strain driving DR Congo's Ebola outbreak still lacks a licensed vaccine because of funding gaps, shifting priorities and the need for efficacy data. A new study found the existing Ervebo vaccine triggers cross-reactive immune responses, but protection remains unproven.
The Democratic Republic of Congo is again at the centre of a major Ebola outbreak, this time caused by the Bundibugyo strain, for which there is still no licensed vaccine or approved treatment. The virus was first identified in 2007 in Uganda, with another outbreak recorded in DR Congo in 2012.
Torsten Feldt, a tropical medicine doctor at Düsseldorf's University Hospital, described the situation as a missed opportunity, saying earlier outbreaks had given the world time to develop vaccines and therapies that was not used. Leonie Mayer, of the German Center for Infection Research (DZIF), said a vaccine could have been developed and pre-clinical trials run earlier, but that effectiveness can only be confirmed during an actual outbreak. She also pointed to limited funding and the prioritisation of other pathogens, noting that many researchers had expected a Sudan virus outbreak and work on that strain is more advanced.
The existing vaccine, Ervebo, is licensed only against the Zaire variant. A recent DZIF study led by Mayer found cross-reactive T-cell responses to Bundibugyo, and to a lesser extent the Sudan virus. Mayer cautioned that the data cannot show whether this response protects people or leads to milder illness.
Experts also warned against mass vaccination without proof of efficacy. Mayer said it would be unethical to deploy a vaccine of unknown effect and would make it impossible to measure whether it works. Jürgen May of the Bernhard Nocht Institute warned it could create false security and erode trust.
Conflict, poor transport links, attacks on health facilities and gaps in contact tracing are also hampering containment. The Tumaini study, now launched in DR Congo, is testing candidates including vaccines from Oxford University and Moderna. Experts estimate a vaccine for widespread use may not be available until mid-2027.